SK Life Science, Inc. introduces Access+ to simplify the Patient support experience. Nov 02, 2026, 10:03 ET New offering brings pharmacy services and patient assistance services together to help patients and healthcare providers more easily navigate the path from prescription to treatment Key Facts: * SK Life Science Access+ launched November 1, 2026, providing patients and healthcare providers with a more integrated experience. * Access+ brings together pharmacy services, home delivery and Patient Assistance Program (PAP) support within one patient support offering. * SK Life Science Access+ Pharmacy provides a new, optional pathway for prescriptions, facilitating intake, benefits verification and applicable support services before routing prescriptions for fulfillment. * Access+ Pharmacy supports patients across coverage types, including commercial insurance, Medicare, Medicaid and SK Life Science's Patient Assistance Program. PARAMUS, N.J., Nov. 2, 2026 /PRNewswire/ - SK Life Science, Inc., a subsidiary of SK Biopharmaceuticals Co., Ltd., today announced the launch of SK Life Science Access+, an innovative approach designed to make it easier and more convenient for patients and healthcare providers to navigate the path from prescription to treatment with XCOPRI(R)(cenobamate tablets) CV, an antiseizure medication approved for the treatment of partial-onset seizures in adults. SK Life Science Access+ creates a more streamlined experience by bringing together key services and support, including the SK Life Science Access+ Pharmacy, the option for home delivery and SK Life Science's Patient Assistance Program support. EXECUTIVE COMMENTARY "Our commitment to the epilepsy community extends beyond advancing treatments to making it easier for patients and healthcare providers to navigate the path to prescribed treatment," said Kristina G. Stracco, Vice President, Market Access, Trade & Patient Services, SK Life Science, Inc. "SK Life Science Access+ provides a reliable, convenient option that helps reduce the burden of navigating the pharmacy process and connects patients with appropriate support services." At the center of the new offering is the SK Life Science Access+ Pharmacy, an optional, centralized, non-dispensing pharmacy pathway available to patients across commercial insurance, Medicare, Medicaid and the Patient Assistance Program. Healthcare providers can prescribe XCOPRI to the SK Life Science Access+ Pharmacy directly in their electronic prescribing system, which facilitates prescription intake, benefits verification and applicable support services before routing prescriptions for fulfillment. Simplifying the path from prescription to treatment Through the SK Life Science Access+ Pharmacy, patients can provide required consent and information as part of the intake process. Their needs can then be assessed, and applicable support services initiated before the prescription is routed for dispensing, with home delivery available where applicable. Access+ also incorporates SK Life Science's Patient Assistance Program for eligible patients. Beginning November 1, the Patient Assistance Program offers a simplified enrollment process that eliminates traditional enrollment forms. For patients referred through SK Life Science Access+ Pharmacy, the electronic prescription serves as the enrollment form, with eligibility assessed through a phone-based process. EXECUTIVE COMMENTARY "Innovation in neuroscience goes beyond developing new treatments. It also means providing patients and healthcare providers with tools that make prescribed treatment easier to obtain," said Donghoon Lee, Chief Executive Officer, SK Life Science, Inc. "SK Life Science Access+ reflects our commitment to making the treatment experience simpler and more convenient for the epilepsy community." The SK Life Science Access+ Pharmacy is searchable through electronic prescribing systems, giving healthcare providers an additional option when prescribing XCOPRI. To learn more about SK Life Science Access+ and the services available to help patients navigate the path from prescription to treatment, visit www.sklsaccess.com. 1. What is SK Life Science Access+? SK Life Science Access+ is an integrated offering designed to help patients who have been prescribed XCOPRI get started and stay on treatment as appropriate. It brings together key services and support, including SK Life Science Access+ Pharmacy, home delivery and SK Life Science's Patient Assistance Program support. 2. Why is SK Life Science introducing Access+? SK Life Science is introducing Access+ to help simplify the process patients and healthcare providers may encounter between prescription and treatment. By bringing key services and support together through a more integrated experience, Access+ is intended to reduce unnecessary complexity and provide a more convenient pathway for patients prescribed XCOPRI. 3. Does Access+ replace SK Life Science Navigator? Yes, all programs previously run through SK Life Science Navigator will now fall under the SK Life Science Access+ program. 4. What happens to patients who were enrolled in SK Life Science Navigator? Patients who were previously enrolled in SK Life Science Navigator will receive a text message from SK Life Science Access+ Pharmacy (1-380-220-7229) about their XCOPRI prescription on or after November 2, 2026. This text message is not spam. To avoid interruption in therapy, patients need to respond to that text message immediately by clicking the link to update their program enrollment and consent. If your patient was previously enrolled in SK Life Science Navigator, but did not receive this text message by December 1, 2026, please reach out to SK Life Science Access+ at 1-866-756-2844. 5. What is SK Life Science Access+ Pharmacy? SK Life Science Access+ Pharmacy is an optional, centralized, non-dispensing pharmacy pathway for XCOPRI prescriptions. Healthcare providers can send an electronic prescription to SK Life Science Access+ Pharmacy, which facilitates prescription intake, benefits verification and applicable support services before routing the prescription for fulfillment. 6. Who can use Access+ Pharmacy? The Access+ Pharmacy pathway can support patients across multiple coverage types, including commercial insurance, Medicare, Medicaid and patients participating in the SK Life Science Patient Assistance Program. 7. How does the Access+ Pharmacy process work? A healthcare provider can electronically prescribe XCOPRI to SK Life Science Access+ Pharmacy. The pharmacy facilitates intake and, if clarification is needed, can contact the healthcare provider. The patient receives a text to provide consent and/or additional information. Access needs are then reviewed, and applicable support pathways can be initiated before the prescription is routed for dispensing. Where applicable, medication can then be delivered to the patient's home. 8. How can healthcare providers find SK Life Science Access+ Pharmacy? SK Life Science Access+ Pharmacy is searchable in electronic medical record systems for electronic prescribing. The field reference guide lists its NPI as 1982514683. 9. Does a healthcare provider have to use SK Life Science Access+ Pharmacy to prescribe XCOPRI? No, Access+ Pharmacy is an optional pathway available to healthcare providers and patients. 10. What types of support are available through Access+? Depending on a patient's circumstances and eligibility, Access+ can help connect patients with services that include pharmacy services, home delivery and the Patient Assistance Program support. 11. Does Access+ provide financial assistance? Financial assistance is one component of the broader Access+ offering, but it is important to distinguish that from the broader meaning of access in this announcement. Access+ is designed primarily to help make the process of obtaining prescribed treatment easier to navigate. Separately, eligible patients may be able to receive financial support through the SK Life Science Patient Assistance Program, subject to applicable eligibility requirements and program terms. 12. What is changing with the SK Life Science Patient Assistance Program? Beginning November 1, enrollment in the SK Life Science Patient Assistance Program will be simplified, eliminating traditional PAP enrollment forms. For patients entering the program through SK Life Science Access+ Pharmacy, the electronic prescription serves as the enrollment form, followed by patient consent and an eligibility assessment. 13. What happens to patients already enrolled in the Patient Assistance Program? Existing PAP patients were transferred to SK Life Science Access+ Pharmacy automatically beginning November 1. According to the transition materials, existing patients' PAP status will remain unchanged through the end of 2026. 14. Is Access+ intended to replace a patient's healthcare provider or pharmacist? No, Access+ is intended to provide an additional pathway and support services around the prescription process. Treatment decisions remain between patients and their healthcare providers, while prescriptions are ultimately routed for dispensing. 15. Does Access+ guarantee that a patient's prescription will be covered? No. Access+ can facilitate benefits verification and help identify applicable support pathways, but individual insurance coverage, eligibility and program requirements still apply. 16. Where can patients and healthcare providers learn more? Patients and healthcare providers can learn more about SK Life Science Access+, including available services and support, by visiting www.sklsaccess.com. About SK Life Science, Inc. and SK Biopharmaceuticals Co., Ltd. SK Life Science, Inc., based in Paramus, New Jersey, is a U.S. subsidiary of SK Biopharmaceuticals Co., Ltd., a global biopharmaceutical company headquartered in South Korea that focuses on developing and commercializing innovative treatments. Together, they are advancing innovative treatments for central nervous system (CNS) disorders and expanding into oncology through next-generation modalities, including radiopharmaceutical therapy (RPT) and targeted protein degradation (TPD), while leveraging AI-driven innovation to accelerate drug development and enhance patient care. For more information, visit sklifescienceinc.com. SK Biopharmaceuticals Co., Ltd. is part of SK Group, South Korea's second-largest conglomerate. SK Group continues to grow in response to the rapidly changing global business environment, demonstrating leadership across key sectors such as semiconductors, energy, ICT and biotechnology. The group is strengthening its leadership position through strategic investments, technological innovation, and global collaboration. With assets of USD 299.1 billion and revenue of USD 171.6 billion in 2025, SK Group is listed in the Fortune Global 500 companies and has 579 subsidiaries and branches worldwide. As a key player in SK Group's biotechnology sector, SK Biopharmaceuticals plays a central role in advancing pharmaceutical innovation, leveraging its integrated capabilities spanning drug discovery, clinical development, regulatory approval, and commercialization to bring innovative treatments to patients worldwide. For more information about SK Biopharmaceuticals, visit www.skbp.com/eng. XCOPRI(R) and ONTOZRY(R) are registered trademarks of SK Biopharmaceuticals Co., Ltd. About XCOPRI(R)(cenobamate tablets) CV Cenobamate is an antiseizure medication (ASM) discovered and developed by SK Biopharmaceuticals and SK Life Science. While the precise mechanism by which cenobamate exerts its therapeutic effect is unknown, it is believed to reduce repetitive neuronal firing by inhibiting voltage-gated sodium currents. It is also a positive allosteric modulator of the γ-aminobutyric acid (GABA[A]) ion channel. Cenobamate is approved in the United States for the treatment of partial-onset seizures in adults and is available under the brand name XCOPRI(R)(cenobamate tablets) CV. Cenobamate can be combined with other ASMs or used alone. The recommended initial dosage of cenobamate is 12.5 mg once-daily, with titration every two weeks; it is available in six tablet strengths for once-daily dosing: 12.5 mg, 25 mg, 50 mg, 100 mg, 150 mg and 200 mg. Cenobamate is also approved in the European Union and the United Kingdom, where it is marketed by Angelini Pharma under the brand name ONTOZRY(R). Its global presence continues to expand across Latin America, Asia, Middle East and North Africa, and other regions through strategic partnerships, with regulatory approvals in more than 45 countries or regions worldwide. IMPORTANT SAFETY INFORMATION AND INDICATION FOR XCOPRI(R)(cenobamate tablets) CV DO NOT TAKE XCOPRI IF YOU: * Are allergic to cenobamate or any of the other ingredients in XCOPRI. * Have a genetic problem (called Familial Short QT syndrome) that affects the electrical system of the heart. XCOPRI CAN CAUSE SERIOUS SIDE EFFECTS, INCLUDING: Allergic reactions: XCOPRI can cause serious skin rash or other serious allergic reactions which may affect organs and other parts of your body like the liver or blood cells. You may or may not have a rash with these types of reactions. Call your healthcare provider right away and go to the nearest emergency room if you have any of the following: swelling of your face, eyes, lips, or tongue, trouble swallowing or breathing, a skin rash, hives, fever, swollen glands, or sore throat that does not go away or comes and goes, painful sores in the mouth or around your eyes, yellowing of your skin or eyes, unusual bruising or bleeding, severe fatigue or weakness, severe muscle pain, frequent infections, or infections that do not go away. Take XCOPRI exactly as your healthcare provider tells you to take it. It is very important to increase your dose of XCOPRI slowly, as instructed by your healthcare provider. QT shortening: XCOPRI may cause problems with the electrical system of the heart (QT shortening). Call your healthcare provider if you have symptoms of QT shortening including fast heartbeat (heart palpitations) that last a long time or fainting. Suicidal behavior and ideation: Antiepileptic drugs, including XCOPRI, may cause suicidal thoughts or actions in a very small number of people, about 1 in 500. Call your health care provider right away if you have any of the following symptoms, especially if they are new, worse, or worry you: thoughts about suicide or dying; attempting to commit suicide; new or worse depression, anxiety, or irritability; feeling agitated or restless; panic attacks; trouble sleeping (insomnia); acting aggressive; being angry or violent; acting on dangerous impulses; an extreme increase in activity and talking (mania); or other unusual changes in behavior or mood. Liver problems: XCOPRI may cause liver problems. Your healthcare provider will do blood tests to check your liver before you start XCOPRI and while you take XCOPRI if needed. Tell your healthcare provider right away if you have any symptoms of liver problems, such as: yellowing of the skin and eyes (jaundice), nausea, vomiting, unusual darkening of the urine, or feeling tired or weak. Nervous system problems: XCOPRI may cause problems that affect your nervous system. Symptoms of nervous system problems include: dizziness, trouble walking or with coordination, feeling sleepy and tired, trouble concentrating, remembering, and thinking clearly, and vision problems. Do not drive, operate heavy machinery, or do other dangerous activities until you know how XCOPRI affects you. Do not drink alcohol or take other medicines that can make you sleepy or dizzy while taking XCOPRI without first talking to your healthcare provider. DISCONTINUATION: Do not stop taking XCOPRI without first talking to your healthcare provider. Stopping XCOPRI suddenly can cause serious problems. Stopping seizure medicine suddenly in a patient who has epilepsy can cause seizures that will not stop (status epilepticus). DRUG INTERACTIONS: XCOPRI may affect the way other medicines work, and other medicines may affect how XCOPRI works. Do not start or stop other medicines without talking to your healthcare provider. Tell healthcare providers about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements. PREGNANCY AND LACTATION: XCOPRI may cause your birth control medicine to be less effective. Talk to your health care provider about the best birth control method to use. Talk to your health care provider if you are pregnant or plan to become pregnant. It is not known if XCOPRI will harm your unborn baby. Tell your healthcare provider right away if you become pregnant while taking XCOPRI. You and your healthcare provider will decide if you should take XCOPRI while you are pregnant. If you become pregnant while taking XCOPRI, talk to your healthcare provider about registering with the North American Antiepileptic Drug (NAAED) Pregnancy Registry. The purpose of this registry is to collect information about the safety of antiepileptic medicine during pregnancy. You can enroll in this registry by calling 1-888-233-2334 or go to www.aedpregnancyregistry.org. Talk to your health care provider if you are breastfeeding or plan to breastfeed. It is not known if XCOPRI passes into breastmilk. Talk to your healthcare provider about the best way to feed your baby while taking XCOPRI. COMMON SIDE EFFECTS: The most common side effects in patients taking XCOPRI include dizziness, sleepiness, headache, double vision, and feeling tired. These are not all the possible side effects of XCOPRI. Tell your healthcare provider if you have any side effect that bothers you or that does not go away. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch. DRUG ABUSE: XCOPRI is a federally controlled substance (CV) because it can be abused or lead to dependence. Keep XCOPRI in a safe place to prevent misuse and abuse. Selling or giving away XCOPRI may harm others and is against the law. INDICATION: XCOPRI is a prescription medicine used to treat partial-onset seizures in adults 18 years of age and older. It is not known if XCOPRI is safe and effective in children under 18 years of age. Please see additional patient information in the Medication Guide. This information does not take the place of talking with your healthcare provider about your condition or your treatment. XCOPRI(R) and ONTOZRY(R) are registered trademarks of SK Biopharmaceuticals Co., Ltd. SOURCE SK Life Science, Inc.

SK Life Science supports SUDEP awareness efforts through partnership with CURE Epilepsy and The Cameron Boyce Foundation. Oct 14, 2026, 11:48 ET SK Life Science to Match Donations Up to $10,000 to Advance SUDEP Research, Awareness, and Education Release Highlights: * SK Life Science to match donations to CURE Epilepsy up to $10,000 * Supporting SUDEP awareness efforts with CURE Epilepsy and The Cameron Boyce Foundation * Raising awareness of a serious but often under-discussed epilepsy-related risk * Reinforcing the need for education, informed conversations, and community empowerment * Advancing SK Life Science's commitment to the epilepsy community PARAMUS, N.J., Oct. 14, 2026 /PRNewswire/ - SK Life Science, Inc., a U.S. pharmaceutical company and part of SK Biopharmaceuticals, today announced its support of SUDEP awareness initiatives led by CURE Epilepsy and The Cameron Boyce Foundation during #StopSUDEP Week, October 19-23, and throughout the month of October. As part of its ongoing commitment to the epilepsy community, SK Life Science will match donations to CURE Epilepsy dollar for dollar up to $10,000, helping advance efforts to raise awareness of Sudden Unexpected Death in Epilepsy (SUDEP), support critical research, and provide educational resources for individuals and families impacted by epilepsy. SUDEP remains one of the most serious epilepsy-related risks. Through its longstanding support of CURE Epilepsy and The Cameron Boyce Foundation, SK Life Science is committed to helping ensure people living with epilepsy and their caregivers have access to information, resources, and conversations that empower them to make informed decisions alongside their healthcare teams. People living with epilepsy can work with their healthcare providers to support seizure management and discuss steps that may help reduce risk, including taking medications as prescribed, recognizing and avoiding personal seizure triggers, getting adequate sleep, limiting alcohol use, and considering nighttime monitoring when appropriate. "Knowledge empowers action, and meaningful conversations can help individuals and families feel more informed and confident in managing epilepsy," said Sunita Misra, Ph.D., M.D., Chief Medical Officer of SK Life Science. "Our research has shown that important conversations about SUDEP are not always reaching the people who need them most. That is why we are proud to support CURE Epilepsy and The Cameron Boyce Foundation in their efforts to raise awareness, encourage dialogue, and ensure the epilepsy community has access to educational resources that can help people better understand and address SUDEP risk." "SUDEP awareness saves lives through knowledge, conversation, and action," said Beth Lewin Dean, MBA, MPA, Chief Executive Officer of CURE Epilepsy. "We are grateful for SK Life Science's partnership and support of this campaign. Together with The Cameron Boyce Foundation and advocates across the epilepsy community, we are all working to ensure more individuals and families have access to information about SUDEP while accelerating the research needed to better understand and ultimately prevent these tragic losses." SK Life Science's support of SUDEP awareness efforts reflects the company's broader commitment to addressing educational gaps within the epilepsy community. Findings from the Hope, Hesitancy and Hard Truths survey revealed that nearly one in five people experiencing daily seizures reported they had either never heard of SUDEP or had not heard about it from their physician. The survey, available on www.sklifescienceinc.com, also found a disconnect between physician and patient discussions, with 88% of physicians reporting they discuss SUDEP compared with just 63% of patients recalling that conversation. These findings underscore the importance of continued education, awareness, and open dialogue about epilepsy-related risks. Throughout October, CURE Epilepsy and The Cameron Boyce Foundation are bringing attention to SUDEP through awareness, education, advocacy, and fundraising initiatives designed to increase understanding of epilepsy and support ongoing research. The campaign encourages individuals, families, healthcare professionals, and advocates to learn about SUDEP, share resources, honor loved ones, and support efforts aimed at reducing epilepsy-related deaths. At SK Life Science, supporting the epilepsy community extends beyond developing medicines. Through partnerships with organizations such as CURE Epilepsy and The Cameron Boyce Foundation, the company remains committed to advancing education, supporting research, and empowering individuals and families affected by epilepsy. For more information about SK Life Science's commitment to the epilepsy community, visit www.sklifescienceinc.com. About SK Life Science, Inc. and SK Biopharmaceuticals Co., Ltd. SK Life Science, Inc., with headquarters in Paramus, New Jersey, is a U.S. subsidiary of SK Biopharmaceuticals Co., Ltd., a pioneering South Korean company in drug development and commercialization. Together, they are advancing innovative treatments for central nervous system (CNS) disorders and oncology, with 12 compounds currently in development. Utilizing target-based drug discovery, high-throughput organic screening/high content screening, computer-aided drug design, combinatorial chemistry, and integrating artificial intelligence across discovery, development, and operations to accelerate innovation, the companies drive R&D efforts in biology/discovery, medicinal chemistry, pharmacology, and clinical development. For more information, visit www.sklifescienceinc.com. SOURCE SK Life Science, Inc.